NASDAQ:IBIO

iBio Q3 2026 Earnings Results & Report

iBio logo
$0.75 +0.04 (+5.86%)
Closing price 04:00 PM Eastern
Extended Trading
$0.76 +0.01 (+1.72%)
As of 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

iBio missed analyst earnings expectations in its Q3 2026 results, released May 12, 2026. The company reported EPS of -$0.07 versus the -$0.06 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2026
Report Date
Time
Before Market Opens
Conference Call
4:00 PM ET

iBio EPS Results

Actual EPS
-$0.07
Consensus EPS
-$0.06
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 6 quarters

iBio Revenue Results

Actual Revenue
N/A
Expected Revenue
$20 thousand
Beat/Miss
N/A
YoY Revenue Growth
N/A

iBio Q3 2026 Earnings FAQ

iBio (NASDAQ:IBIO) reported earnings of -$0.07 per share for Q3 2026, missing the consensus estimate of -$0.06. The report was announced on Tuesday, May 12, 2026.

iBio Earnings Headlines

Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.tc pixel
Brookline Capital Markets Boosts Earnings Estimates for iBio
See More iBio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like iBio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on iBio and other key companies, straight to your email.

About iBio

iBio (NASDAQ:IBIO) is a biotechnology company focused on using artificial intelligence and other computational tools to discover and develop therapies. Its research has included programs targeting obesity and metabolic diseases, as well as oncology.

The company’s current approach builds on its earlier work in biologics manufacturing. Historically, iBio used its plant-based FastPharming platform to produce proteins and antibodies for research and therapeutic development.

iBio is based in the United States and has shifted its focus from plant-based biologics production toward AI-enabled drug discovery. Its programs are in development, and the company’s research priorities may change as its pipeline advances.

View iBio Profile